Literature DB >> 26416004

Trastuzumab is not a tyrosine kinase inhibitor.

Nishant Mohan1, Wen Jin Wu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26416004     DOI： 10.1038/nrcardio.2015.135

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

Review 1.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

Review 2.  Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Authors:  Patrick J Medina; Susan Goodin
Journal:  Clin Ther       Date:  2008-08       Impact factor: 3.393

Review 3.  Epidermal growth factor receptor targeting in cancer.

Authors:  John Mendelsohn; Jose Baselga
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

4.  p185HER2 signal transduction in breast cancer cells.

Authors:  G K Scott; J M Dodson; P A Montgomery; R M Johnson; J C Sarup; W L Wong; A Ullrich; H M Shepard; C C Benz
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

Review 5.  Cardiotoxicity of anticancer treatments.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2015-05-12       Impact factor: 32.419

Review 6.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

7.  Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Authors:  Simone Diermeier; Gábor Horváth; Ruth Knuechel-Clarke; Ferdinand Hofstaedter; János Szöllosi; Gero Brockhoff
Journal:  Exp Cell Res       Date:  2005-01-21       Impact factor: 3.905

8.  Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.

Authors:  Milos Dokmanovic; Yun Wu; Yi Shen; Jieqing Chen; Dianne S Hirsch; Wen Jin Wu
Journal:  Cancer Biol Ther       Date:  2014-05-16       Impact factor: 4.742

9.  HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.

Authors:  Merel Gijsen; Peter King; Tim Perera; Peter J Parker; Adrian L Harris; Banafshé Larijani; Anthony Kong
Journal:  PLoS Biol       Date:  2010-12-21       Impact factor: 8.029
  9 in total
  2 in total

1.  Mechanisms underlying trastuzumab activity are complex.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

2.  Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Authors:  Nishant Mohan; Jiangsong Jiang; Milos Dokmanovic; Wen Jin Wu
Journal:  Antib Ther       Date:  2018-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.